Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
1960
|
| gptkbp:ATCCode |
C03DA01
|
| gptkbp:CASNumber |
52-01-7
|
| gptkbp:chemicalFormula |
C24H32O4S
|
| gptkbp:contraindication |
hyperkalemia
anuria acute renal insufficiency |
| gptkbp:drugClass |
potassium-sparing diuretic
aldosterone antagonist |
| gptkbp:eliminationHalfLife |
1.4 hours (spironolactone), 13.8 hours (canrenone metabolite)
|
| gptkbp:excretion |
urine
bile |
| gptkbp:genericName |
gptkb:spironolactone
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aldactone
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
drowsiness
gynecomastia gastrointestinal upset hyperkalemia menstrual irregularities |
| gptkbp:usedFor |
heart failure
edema hypertension hypokalemia hirsutism primary hyperaldosteronism |
| gptkbp:bfsParent |
gptkb:spironolactone
|
| gptkbp:bfsLayer |
7
|